Format

Send to

Choose Destination
Urol Case Rep. 2019 Jan 30;24:100839. doi: 10.1016/j.eucr.2019.100839. eCollection 2019 May.

Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report.

Author information

1
Department of Urology, Iwate Medical University School of Medicine, 19-1, Uchimaru, Morioka-shi, Iwate, 020-8505, Japan.
2
Department of Urology, Iwate Prefectural Ofunato Hospital, 10-1, Yamaumagoe, Ofunato-shi, Iwate, 022-8512, Japan.
3
Department of Pathology, Iwate Prefectural Ofunato Hospital, 10-1, Yamaumagoe, Ofunato-shi, Iwate, 022-8512, Japan.

Abstract

We report a case of 59-year-old woman who has multiple lung metastases with renal cell carcinoma (RCC). She received neoadjuvant therapy using nivolumab following sunitinib. Thereafter, we performed cytoreductive nephrectomy and subsequently administered nivolumab. We also found a high expression of PD-L1 in tumor cell and infiltration of lymphocytes with CD8 expression by immunohistochemistry. A complete response was achieved 4 months after surgery. A perioperative treatment using nivolumab might be useful treatment for metastatic RCC.

KEYWORDS:

C-relative protein; CR; CRP; CT; Complete response; Computed tomography; H&E; Hematoxylin and eosin; IHC; IHCs; Immunocheckpoint therapies; Immunohistochemistry; KPS; Karnofsky performance status; Neoadjuvant; Nivolumab; PD-1; PD-L1; Programmed death ligand-1; Programmed death-1; RCC; Renal cell carcinoma

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center